Celiac.com 05/21/2026 - This study looks at an important question involving celiac disease and the immune system. The researchers focused on people with very low levels of immunoglobulin A, which is a key antibody that helps protect the body, especially in areas like the digestive tract. This deficiency is the most common primary immune deficiency and has already been linked to celiac disease in earlier research.

The study also examined a specific genetic marker called HLA-DQB1*02:01. This gene variant is already known to be connected with celiac disease risk. Because both low immunoglobulin A levels and celiac disease appear to share some genetic background, the researchers wanted to see whether this genetic marker might also be tied to lower total immunoglobulin A levels in otherwise healthy people.

Why This Question Matters

Celiac disease is strongly influenced by genetics, and certain human leukocyte antigen markers are known to increase risk. At the same time, immunoglobulin A deficiency is more common in people with celiac disease than in the general population. This overlap has made researchers wonder whether the same genetic factors may help explain both conditions.

If a gene linked to celiac disease also affects immunoglobulin A levels, that could help explain why some people are more likely to develop immune problems that complicate diagnosis. This is especially important because many celiac blood tests depend on normal immunoglobulin A levels. When those levels are too low, standard testing may be less reliable and cases can be missed.

How the Study Was Carried Out

The researchers analyzed 108 serum samples from people in a bone marrow donor registry. They measured each donor’s total immunoglobulin A concentration and compared those values according to whether the person carried the HLA-DQB1*02:01 variant.

The researchers first looked at the overall group and compared immunoglobulin A levels between people who carried the gene variant and those who did not. Then they performed a smaller follow-up analysis focusing only on donors whose immunoglobulin A levels were on the low side, defined as less than 80 milligrams per deciliter.

This second step was important because a gene effect might be easier to detect in people who are already closer to deficiency, even if it does not stand out in the full group.

What the Researchers Found

When looking at all 108 donors together, the study did not find a meaningful difference in total immunoglobulin A levels between carriers of HLA-DQB1*02:01 and people who did not carry the variant. In other words, across the whole sample, the gene was not linked to higher or lower immunoglobulin A in a clear way.

However, the picture changed in the subgroup with lower immunoglobulin A levels. In that smaller analysis, the researchers found a statistically significant difference between people who carried HLA-DQB1*02:01 and those who did not. This included both people with one copy and people with two copies of the gene variant.

That finding suggests the gene may play a role in shaping immunoglobulin A levels in people who are already predisposed to lower levels, even if that effect is not obvious in the broader population.

What the Results May Mean

The study does not prove that HLA-DQB1*02:01 directly causes immunoglobulin A deficiency. But it does raise the possibility that this gene variant may influence how low immunoglobulin A levels become in people who are already vulnerable.

This is an important distinction. The results do not show a universal effect in everyone. Instead, they hint that the genetic variant may matter more in a selected group, especially among people who already have low immunoglobulin A or may be at risk of deficiency.

That idea fits with what is already known about celiac disease. Many people carry genetic risk markers, but not all of them develop disease. Genes may not act alone. Instead, they may interact with other inherited traits, immune patterns, and environmental triggers.

Why the Findings Should Be Interpreted Carefully

The authors describe this as a preliminary study, and that is important. The number of samples was fairly small, especially once the researchers narrowed their attention to the lower-immunoglobulin group. A finding in a small subgroup can be interesting, but it needs to be confirmed in larger studies before strong conclusions can be made.

Another point is that this study involved donors from a registry rather than patients already diagnosed with celiac disease or immunoglobulin A deficiency. That makes the findings useful for exploring patterns, but it also means the results may not fully reflect what happens in real clinical populations.

The authors themselves note that larger and more standardized research will be needed to confirm whether this gene truly affects immunoglobulin A levels in a meaningful and consistent way.

How This Connects to Celiac Disease

This study is especially relevant to celiac disease because immunoglobulin A plays a major role in screening for the condition. Many of the most common blood tests for celiac disease rely on this antibody. If a patient has immunoglobulin A deficiency, those tests may come back falsely normal even when celiac disease is present.

Because of that, understanding why some people have low immunoglobulin A is more than a scientific detail. It could help doctors recognize which patients may need a different testing approach. It could also improve awareness of why celiac disease sometimes goes undetected in people who clearly have symptoms.

If future research confirms that HLA-DQB1*02:01 helps shape immunoglobulin A levels in at-risk individuals, that may strengthen the idea that celiac disease and immunoglobulin A deficiency are connected through shared genetic pathways.

Why This Study Matters for People With Celiac Disease

This study explored whether a gene strongly associated with celiac disease might also influence total immunoglobulin A levels. In the full sample, the researchers did not find a difference between carriers and non-carriers. But among donors with lower immunoglobulin A levels, they did find a significant difference linked to the gene variant.

That does not settle the question, but it offers an intriguing clue. The results suggest that HLA-DQB1*02:01 may help shape immunoglobulin A levels in people who are already predisposed to deficiency. More research will be needed to determine whether this relationship is real, how strong it is, and how it may affect patient care.

For people with celiac disease, this study could be meaningful because it points toward a possible genetic link between celiac risk and low immunoglobulin A levels. That matters because low immunoglobulin A can make celiac disease harder to detect with standard blood tests. A better understanding of this connection could eventually lead to more accurate diagnosis, earlier detection, and fewer missed cases in people who are genetically vulnerable.

Read more at: link.springer.com

Celiac.com 05/19/2026 - Celiac disease may sound straightforward on paper, but in real life it is often difficult to diagnose correctly. Many people think diagnosis is simple: run a blood test, confirm it with a small intestine biopsy, and begin a gluten-free diet. In practice, however, each step has weaknesses that can lead to missed cases, delayed answers, or even incorrect diagnoses.

This review examines the many ways the diagnostic process can go wrong. It explains that celiac disease can look very different from person to person, and that the usual testing methods do not always give clear results. Some people have classic digestive symptoms, but many others do not. Some have anemia, bone loss, nerve problems, fertility problems, or vague symptoms that do not immediately suggest celiac disease. As a result, many adults go undiagnosed for years while intestinal damage continues.

Why Standard Blood Testing Is Not Always Enough

Blood testing is often the first step when celiac disease is suspected. These tests look for immune reactions linked to gluten exposure. While useful, they are not perfect. A major problem is that some people do not make enough of one key antibody type for the usual tests to work properly. In those cases, the standard test can look normal even when the person truly has celiac disease.

The review stresses that doctors should not rely on a single blood result without considering the full picture. Borderline results can be especially confusing. A weak positive result may reflect early disease, changing gluten intake, or even a condition other than celiac disease. At the same time, a false negative result can happen if the person has already reduced gluten before testing. That is important because many people try a gluten-free diet on their own before seeing a specialist, which can make both blood tests and biopsy findings less reliable.

Another issue is that laboratory testing is not perfectly standardized. Different test systems may not perform exactly the same way. This means one laboratory may classify a result differently from another. For people being followed over time, that inconsistency can complicate decisions and add confusion.

Biopsy Problems Can Also Lead to Missed Diagnoses

Many people assume that a biopsy settles the matter once and for all. The review makes clear that this is not always true. A biopsy can miss celiac disease if the tissue samples are taken from the wrong location or if too few samples are collected. Damage in celiac disease may be patchy, meaning one area of the small intestine may look abnormal while another appears normal.

This is especially important in the upper part of the small intestine. The review explains that some adults have disease limited to the duodenal bulb, which is an early section of the small intestine. If this area is not sampled, the biopsy may miss the disease entirely. Because of this, the authors emphasize that doctors should take multiple samples from more than one location.

Even when enough tissue is collected, interpretation can still be difficult. Pathologists must judge how much inflammation and damage is present, and the earliest changes are not always obvious. One expert may call the findings abnormal while another may be less certain. This subjectivity can delay diagnosis, particularly in mild or unusual cases.

Other Conditions Can Mimic Celiac Disease

One of the biggest diagnostic traps is that celiac disease is not the only illness that can damage the lining of the small intestine. Certain infections, medication effects, immune disorders, and bacterial overgrowth can all create biopsy patterns that resemble celiac disease. This means that an abnormal biopsy does not automatically prove the diagnosis.

The review warns that doctors must consider these look-alike conditions carefully. Without that caution, a patient may be incorrectly labeled as having celiac disease and told to follow a lifelong gluten-free diet when another explanation is actually responsible. This can create years of unnecessary restriction while the real illness remains untreated.

The same problem can happen in reverse. A person may truly have celiac disease, but because their test results are not typical, the condition may be dismissed as something else. The review repeatedly shows that diagnosis works best when blood tests, biopsy findings, symptoms, diet history, and clinical judgment are all considered together.

Genetic Testing Has Limits

Genetic testing can be helpful, but it is often misunderstood. Many people with celiac disease carry certain genetic markers, yet those markers are also common in the general population. That means a positive genetic test does not prove that someone has celiac disease. It only shows that the disease is possible.

Where genetic testing is most useful is in ruling celiac disease out. If a person lacks the key genetic pattern linked to the disease, celiac disease becomes very unlikely. The review suggests that this can help in confusing cases, especially when someone has already started a gluten-free diet before proper testing or when blood and biopsy results do not agree.

Special Cases Make Diagnosis Even Harder

Some people fall outside the usual pattern altogether. One example is seronegative celiac disease, where a person has intestinal damage and symptoms consistent with celiac disease but negative blood tests. Another example is potential celiac disease, where blood tests are positive but the biopsy has not yet shown clear damage. These cases require more careful follow-up and often cannot be resolved with a simple one-time test.

The review also discusses patients who continue to have symptoms even after adopting a gluten-free diet. In some cases, they may have another overlapping condition, such as microscopic colitis or small intestinal bacterial overgrowth. In more serious cases, persistent symptoms may point to refractory disease or even lymphoma linked to longstanding intestinal injury. These are situations where additional imaging, repeat testing, and specialist evaluation become important.

New Diagnostic Tools May Improve the Future

The authors also describe newer approaches that may eventually improve diagnosis. These include markers of direct intestinal injury, small genetic regulators found in blood or tissue, and patterns in the gut microbiome. These tools are not yet ready to replace current testing, but they may one day help doctors identify celiac disease earlier or follow patients more accurately over time.

This is encouraging because current testing leaves too much room for uncertainty. Better tools could reduce the number of patients who spend years searching for answers or who are misdiagnosed along the way.

Why This Study Matters for People with Celiac Disease

This study is meaningful because it shows that diagnosing celiac disease is not just a matter of ordering one blood test or performing one biopsy. Mistakes can happen at every stage. People may be tested after they have already stopped eating gluten, blood tests may fail in certain immune states, biopsies may miss patchy disease, and other illnesses can look very similar. All of this can lead to delayed diagnosis or the wrong diagnosis.

For people who have celiac disease, this review matters because it highlights why persistence and proper testing are so important. It supports a more careful and complete approach that can help patients get accurate answers sooner. A correct diagnosis does more than put a name on symptoms. It can prevent long-term harm, guide treatment, and help people avoid years of confusion while living with an undetected disease.

Read more at: xiahepublishing.com

Watch the video version of this article:

Watch the super short video version of this article:

Celiac.com 05/12/2026 - Celiac disease is commonly understood as an immune reaction to gluten that damages the small intestine. While avoiding gluten remains the primary treatment, this study explores an important question: are there other factors inside the gut that influence how the disease develops and heals?

Researchers focused on the role of gut bacteria and how they process dietary fiber. Their findings suggest that changes in these bacteria may affect inflammation, healing, and overall intestinal health in people with celiac disease.

The Role of Gut Bacteria in Digestive Health

The human gut contains trillions of bacteria that help digest food, produce nutrients, and regulate the immune system. One of their key roles is breaking down dietary fiber, which humans cannot digest on their own.

When gut bacteria process fiber, they produce beneficial substances that support intestinal health, reduce inflammation, and help maintain a balanced digestive environment. These substances are especially important in protecting the lining of the intestine.

This study investigated whether this fiber-processing function is altered in people with celiac disease.

What the Study Looked At

The researchers compared three groups of people:

• Individuals newly diagnosed with celiac disease
• People with celiac disease who had been following a gluten-free diet for at least two years
• Healthy individuals without celiac disease

They analyzed samples from the small intestine and stool to examine the types of bacteria present and how effectively those bacteria could process fiber.

They also used laboratory mouse models to better understand how dietary fiber and specific bacteria influence intestinal healing.

Key Finding: Reduced Fiber Processing in Celiac Disease

One of the most important discoveries was that people with celiac disease had a reduced ability to process fiber in the small intestine. This was true both for those newly diagnosed and for those already following a gluten-free diet.

The study found that certain beneficial bacteria responsible for breaking down fiber were less abundant in individuals with celiac disease. This reduction was not simply due to diet differences, suggesting a deeper imbalance in the gut.

Visual data presented in the early figures of the study showed clear differences in bacterial diversity and composition between healthy individuals and those with celiac disease.

Lower Production of Helpful Gut Compounds

Because fiber was not being processed as efficiently, people with celiac disease produced lower levels of beneficial compounds created during fiber digestion.

These compounds play a key role in:

• Reducing inflammation
• Supporting the intestinal lining
• Helping regulate immune responses

According to the data shown in mid-study charts, individuals with active celiac disease had the lowest levels of these protective compounds, while those on a gluten-free diet showed partial improvement.

Diet Alone Does Not Fully Explain the Problem

Interestingly, the study found that fiber intake was generally low across all groups, including healthy individuals. However, this alone did not explain the differences in gut function.

Even when people consumed similar amounts of fiber, those with celiac disease still showed reduced ability to process it. This suggests that the issue is not just what people eat, but how their gut bacteria function.

The analysis of dietary patterns confirmed that while gluten-free diets change food choices, they do not fully account for the observed microbial differences.

Testing Fiber and Healing in a Controlled Setting

To better understand cause and effect, researchers used specially designed mouse models that mimic aspects of celiac disease. These mice were exposed to gluten and then switched to a gluten-free diet.

Some of the mice were given additional dietary fiber, while others were not.

The results were striking:

• Mice that received certain types of fiber healed faster
• They showed improved intestinal structure and reduced inflammation
• Mice without added fiber recovered more slowly

Images of intestinal tissue in the study clearly show healthier structures in mice that received fiber compared to those that did not.

Why Certain Fibers Worked Better: Inulin Performed Best Overall

Not all types of fiber had the same effect. One specific type of fiber stood out for its ability to improve healing.

This fiber increased the production of beneficial compounds in the small intestine and supported a healthier gut environment. It also worked without dramatically changing the overall composition of gut bacteria, suggesting it improved function rather than simply altering which bacteria were present.

The study also found that inulin increased small-intestinal SCFA production, mainly acetate, while HylonVII did not show the same SCFA benefit. The authors specifically state that inulin-supported microbial fiber metabolism accelerated mucosal healing during the gluten-free diet.

The Importance of Specific Bacteria

The study highlighted a group of bacteria that are particularly good at breaking down fiber. These bacteria were found at lower levels in people with celiac disease.

When researchers introduced these bacteria into controlled laboratory conditions, they observed increased production of beneficial compounds—especially when fiber was available.

This suggests that both the presence of the right bacteria and the availability of the right type of fiber are necessary for optimal gut health.

A Cycle of Imbalance in the Gut

The findings point to a cycle that may occur in celiac disease:

• Loss of fiber-processing bacteria reduces beneficial compound production
• Lower levels of these compounds lead to more inflammation
• Inflammation further disrupts the gut environment

This cycle may help explain why some people continue to experience symptoms or slow healing even after removing gluten from their diet.

Limitations and Areas for Future Research

The researchers noted that their study had some limitations, including a relatively small number of human participants and challenges in directly measuring certain compounds in the small intestine.

However, the combination of human data and controlled laboratory experiments provides strong support for their conclusions.

Future studies may explore whether targeted dietary changes or therapies that restore beneficial bacteria could improve outcomes for people with celiac disease.

Conclusion: Why This Study Matters for People with Celiac Disease

This study offers an important new perspective on celiac disease by showing that gut bacteria and fiber metabolism play a significant role alongside gluten.

It suggests that even after adopting a gluten-free diet, some underlying issues in the gut may persist, affecting healing and overall health.

For people with celiac disease, these findings highlight the potential value of focusing not only on avoiding gluten but also on supporting gut health through diet and possibly future treatments.

In the future, personalized approaches that combine a gluten-free diet with strategies to improve gut bacteria and fiber metabolism may offer better outcomes and improved quality of life.

Read more at: nature.com

Watch the video version of this article:

Watch the super short video version of this article:

Celiac.com 05/11/2026 - Celiac disease is widely known as a condition triggered by gluten that damages the small intestine. However, the underlying processes that drive this damage are complex and still being explored. This study takes a closer look at how inflammation inside the gut interacts with a natural cellular process called autophagy, which helps cells clean up and recycle damaged components.

By studying both patient tissue samples and lab-grown intestinal models, researchers aimed to understand how these two processes influence each other and contribute to the disease.

What Is Autophagy and Why Does It Matter?

Autophagy is a basic function inside cells that acts like a recycling system. It removes damaged parts and helps maintain balance within the cell. When this process works properly, it supports healthy cell function and helps control inflammation.

In celiac disease, this study found that autophagy does not work as efficiently as it should. When this cleanup system slows down, harmful substances and signals can build up inside cells, potentially triggering or worsening inflammation.

How the Study Was Conducted

Researchers examined intestinal tissue from children with active celiac disease, those following a gluten-free diet, and individuals without the condition. They also created intestinal organoids, which are miniature lab-grown versions of the gut that mimic how intestinal cells behave.

These organoids allowed scientists to test how different conditions affect inflammation and cell function. They also used specific compounds to either block or stimulate the cell cleanup process to observe how these changes influenced inflammation.

Key Finding: Reduced Cellular Cleanup in Celiac Disease

The study found clear signs that the cell cleanup process was impaired in people with celiac disease. This was true not only in those actively consuming gluten but also in those already following a gluten-free diet.

Markers associated with damaged or unprocessed cellular material were significantly higher in celiac samples. This suggests that the cells were struggling to properly remove waste and maintain balance.

Visual evidence from tissue imaging, such as the staining patterns shown in the figures on early pages of the study, confirmed that these changes were present directly in the intestinal lining.

Inflammation Remains Active Even Without Gluten

One of the most important findings is that inflammation does not completely disappear when gluten is removed from the diet. While it may be reduced, signs of ongoing immune activity were still present in patients who were no longer consuming gluten.

This suggests that celiac disease involves deeper, long-lasting changes in the gut that are not entirely reversed by diet alone.

The Role of the mTOR Pathway

The study also identified increased activity in a cellular pathway that controls growth and stress responses. This pathway becomes more active when cells are under pressure, such as during inflammation.

When the cell cleanup system is impaired, this pathway becomes overactive, further promoting inflammation and disrupting normal cellular balance.

Experimenting with Cell Function: Blocking and Restoring Balance

To better understand cause and effect, researchers manipulated the system in lab-grown intestinal cells.

• When they blocked the cleanup process, inflammation increased.
• When they stimulated the cleanup process, inflammation decreased.

This clearly demonstrated a direct relationship between these two processes. When cells cannot properly clean themselves, inflammation worsens. When cleanup improves, inflammation can be reduced.

Inflammatory Signals Spread the Problem

The study also showed that inflammatory substances released by affected cells can influence nearby healthy cells. When healthy intestinal cells were exposed to these signals, they began to show the same problems—reduced cleanup ability and increased inflammation.

This finding suggests that inflammation in celiac disease may spread through the gut, amplifying the overall response.

Data from the charts showing multiple inflammatory markers, such as those displayed in the mid-section figures of the study, illustrate how widespread these signals can be.

A Network of Inflammation in the Gut

The researchers identified a complex network of inflammatory molecules that interact with each other. These molecules are involved in immune signaling, cell communication, and tissue repair.

Analysis of this network revealed strong connections between different inflammatory pathways. These interactions help explain why celiac disease can be persistent and difficult to fully control.

Even in patients on a gluten-free diet, some of these inflammatory signals remained elevated, indicating a lingering imbalance in the gut environment.

What This Means for Understanding Celiac Disease

This study suggests that celiac disease is not just a reaction to gluten but also involves deeper changes in how intestinal cells function. Problems with cellular cleanup and ongoing inflammation appear to reinforce each other, creating a cycle that can persist over time.

These findings may help explain why some patients continue to experience symptoms even after removing gluten from their diet.

Potential Future Directions

The results open the door to new ways of thinking about treatment. Instead of focusing only on removing gluten, future therapies might aim to:

• Improve cellular cleanup processes
• Reduce underlying inflammation
• Interrupt the cycle between inflammation and cell dysfunction

While more research is needed, this approach could lead to more comprehensive management of the disease.

Conclusion: Why This Study Matters

This research provides important insight into the biological processes behind celiac disease. It shows that inflammation and impaired cellular repair are closely linked and may continue even after dietary changes.

For people with celiac disease, this helps explain why symptoms can persist and why healing may take time. It also highlights the importance of ongoing monitoring and the potential for new treatments that go beyond diet alone.

Ultimately, this study moves us closer to understanding celiac disease as a complex condition involving both immune responses and cellular function, offering hope for better care and improved quality of life in the future.

Read more at: nature.com

Watch the video version of this article:

Watch the super short video version of this article:

Celiac.com 03/26/2026 - People with celiac disease often work hard to avoid gluten, yet many still experience symptoms. Some symptoms are tied to accidental gluten exposure, while others may be caused by different digestive problems, stress, or slow healing. As new treatments for celiac disease are being developed, researchers need reliable ways to measure whether a therapy truly improves how people feel. That is where standardized symptom tracking tools become important.

This study evaluated a daily symptom diary called the Celiac Disease Symptom Diary version 2.1. The goal was to test whether the diary works well as a measure of symptom severity. In plain terms, the researchers wanted to know whether the diary is consistent, trustworthy, and able to detect meaningful changes in symptoms over time.

What the Symptom Diary Measures

The diary focuses on five core symptoms that many people with celiac disease recognize: abdominal pain, bloating, diarrhea, nausea, and tiredness. Each evening, participants rated the worst level (peak severity) they experienced in the prior twenty-four hours using a simple scale ranging from none to very severe. The diary also included a separate set of daily counts for vomiting episodes and bowel movements, including loose stool patterns.

From these daily entries, researchers calculated weekly scores. They looked at two styles of weekly summaries: an “average” score (how symptoms looked on average across the week) and a “worst” score (the worst day captured within the week). They also created combined summary scores that grouped the digestive symptoms together and another that included tiredness as well.

How the Study Was Run

The data came from a twelve-week observational study conducted virtually in the United States. Adults and adolescents who had already been diagnosed with celiac disease participated from home using an application on a smartphone or tablet. Participants were required to be following a gluten-free diet for at least six months and to have had celiac-related symptoms within the prior three months.

In addition to completing the daily diary, participants periodically completed other established questionnaires about digestive symptoms and overall symptom severity. These additional questionnaires were used as “comparison tools” to test whether the diary behaves the way a good symptom measure should. For example, if someone reports worse symptoms on another well-known questionnaire, the diary should also show worse scores.

Who Participated

In total, 480 people completed the study, including 338 adults and 142 adolescents. The average time since diagnosis was several years, and most participants reported relatively mild symptoms overall, which is not surprising because they were already on a gluten-free diet. Even so, participants used the full range of response choices, meaning the diary captured both low-symptom days and more difficult days.

The study also tracked missing entries. Most participants completed the diary consistently, though missing days increased somewhat over time. Importantly, the diary system was set up to prevent partial entries, so a missed day meant the entire diary was not completed that day.

Did the Diary Show Reliable, Consistent Results?

A major question for any symptom tool is reliability. A reliable tool gives stable results when a person’s symptoms have not truly changed. The researchers tested reliability in two ways.

First, they looked at whether the symptom items “fit together” in a sensible way when combined into weekly summary scores. They found that the combined weekly digestive symptom score had strong internal consistency. In practical terms, this suggests the diary items relate to a shared underlying experience of digestive symptom burden, without being so repetitive that they are essentially the same question asked multiple times.

Second, they tested whether the weekly scores stayed similar from one week to the next among people who said their overall symptom severity had not changed. The results showed high stability for the main weekly digestive symptom score. This supports the idea that if a person’s symptoms are steady, the diary will not create artificial swings.

Did the Diary Measure What It Was Supposed to Measure?

Another key question is validity: does the diary actually measure celiac-related symptom severity in a meaningful way?

To test this, the researchers compared diary scores with other symptom questionnaires used in digestive research. They expected that the diary’s digestive symptom scores would correlate more strongly with questionnaires that also emphasize digestive symptoms, and less strongly with measures that capture broader or different symptom concepts.

The results generally matched expectations. The weekly digestive symptom scores had moderate to strong relationships with digestive symptom domains from other questionnaires, especially areas that aligned closely with abdominal pain and diarrhea. This supports the idea that the diary is capturing real symptom burden rather than random noise.

The researchers also tested whether the diary could distinguish between “known groups.” Participants rated their overall symptom severity on a separate one-question measure. When participants placed themselves in worse categories, the diary’s weekly scores were also higher. This is a straightforward but important finding: the diary aligns with how patients describe their own symptom severity.

Could the Diary Detect Symptom Improvement or Worsening?

Detecting change matters most in clinical trials. If a future therapy reduces symptom severity, researchers need a tool that can reflect that improvement.

In this study, there was no new treatment being tested, so the researchers evaluated change in a practical way. They compared diary score changes over time to changes in participants’ own global ratings of symptom severity. In adults, the pattern was clear: people who reported feeling better tended to show lower diary scores, and people who reported worsening tended to show higher scores. This indicates that the diary is sensitive enough to track symptom shifts over time.

Among adolescents, the change patterns were less clear. The authors suggested that this may be due to smaller sample size, limited symptom movement over the study period, and the lack of an intervention. The adolescent results were still useful, but the study suggests that additional research in adolescents would strengthen confidence in how well the diary captures change in that age group.

What Counts as a Meaningful Change?

Even when a symptom score changes, the real question is whether the change is large enough to matter to a patient. The study estimated “meaningful change thresholds,” which are best thought of as rough guideposts for what level of improvement might feel noticeable or important.

For adults, the study proposed a small but measurable improvement threshold for the weekly average digestive symptom score and the weekly average total symptom score (which includes tiredness). The study also proposed larger improvement thresholds for the “worst” weekly scores, which are more sensitive to the single most difficult day in a week. For adolescents, meaningful change thresholds could be estimated for the worst weekly scores, but not confidently for the weekly average scores, again reflecting the limitations noted above.

Why This Matters for People With Celiac Disease

For the celiac community, this study supports a practical idea: daily symptom tracking can be standardized and tested in a way that makes it useful for medical research. If new treatments are being developed to help people who remain symptomatic despite a gluten-free diet, researchers need tools that can clearly show whether symptoms are improving. A well-tested diary like this can help ensure that clinical trial results reflect real patient experiences, not just laboratory measures.

This work also highlights the value of virtual research. By allowing participants to enroll remotely and report symptoms daily through an application, the study gathered a large amount of real-world symptom data with relatively low dropout and strong engagement.

While the diary does not capture every possible celiac-related complaint, especially symptoms outside the digestive system, it offers a focused way to track a core set of symptoms that many patients and clinicians care about. Over time, tools like this may help accelerate the development and evaluation of therapies that reduce symptom burden, support better quality of life, and offer options beyond diet alone for people who continue to struggle.

Read more at: dovepress.com

Celiac.com 03/24/2026 - Celiac disease is a lifelong immune condition triggered by gluten in genetically susceptible individuals. The only effective treatment is complete avoidance of gluten. While this sounds straightforward, maintaining a strict gluten-free diet can be complex, socially challenging, and nutritionally risky without proper guidance.

National and international guidelines recommend that adults with celiac disease receive an annual review with a dietitian. These reviews are important to assess dietary adherence, nutritional status, symptom control, and long-term health risks such as low bone density or vitamin deficiencies. However, many health systems struggle to provide consistent annual appointments due to limited specialist availability and increasing patient numbers.

This study explored whether a digital annual review tool could provide an effective alternative for clinically stable adults living with celiac disease.

What the Researchers Set Out to Study

The researchers evaluated a digital “virtual annual review” questionnaire designed by specialist dietitians. The tool was sent to adults who had been diagnosed with celiac disease for more than three years and were considered clinically stable. Stability meant they had no ongoing concerning symptoms, were following a gluten-free diet, and had responded well to treatment at their last review.

The questionnaire assessed symptoms, dietary adherence, quality of life, and patient satisfaction. Once completed, a specialist dietitian reviewed the responses and determined whether further follow-up was needed.

The study had two main goals:

• To determine whether age, sex, ethnicity, or length of diagnosis affected engagement with the digital tool.
• To assess how efficient the tool was in terms of dietitian review time and follow-up decisions.

High Engagement Across Demographics

More than eighty percent of eligible participants completed the digital annual review. Importantly, engagement was not significantly affected by age, biological sex, ethnicity, or how long a person had been diagnosed.

This finding challenges common assumptions that older adults are less likely to engage with digital healthcare tools. A meaningful portion of participants over the age of sixty-three completed the digital review successfully. Some participants required help from family members or administrative support, but overall engagement remained strong.

These results suggest that digital care may be more broadly accessible than previously assumed, particularly when introduced as part of routine care rather than as an abrupt replacement.

Most Patients Did Not Require Additional Follow-Up

After reviewing the digital responses, dietitians determined that nearly three-quarters of participants did not need any additional contact before their next annual review. In other words, the digital tool was sufficient to confirm that their condition remained stable.

About one in five participants required a follow-up appointment within six months, typically due to symptoms or concerns about gluten-free diet adherence. A small percentage required a brief clarification call before a final decision was made.

This structured triage process allowed clinicians to focus more intensive care on those who needed it, while reducing unnecessary appointments for those who were stable.

Time Efficiency for Dietitians

One of the most striking findings was the time saved. The median time required for a dietitian to review and triage a completed digital form was fourteen minutes. In comparison, a traditional in-person appointment typically lasts around thirty minutes.

This suggests that the digital approach reduced review time by roughly half. Time savings at scale could allow clinics to accommodate more new patients, shorten wait times, and reallocate resources toward complex cases.

In addition to clinician time, patients also benefited from avoiding travel, parking costs, and time away from work or family responsibilities.

Patient Preferences for Future Reviews

More than half of participants stated they preferred using the digital tool again for future annual reviews. Others preferred in-person or telephone appointments, and some requested earlier follow-up intervals.

This diversity of preferences highlights an important lesson: digital tools should expand options rather than replace traditional care entirely. Different individuals require different levels of support, and flexibility may be the key to improving long-term engagement.

Strengths and Limitations of the Approach

The digital questionnaire allowed for self-reporting in a private, structured format. Some research suggests that people may disclose sensitive information more honestly in written digital formats than in face-to-face appointments. This could potentially improve detection of accidental gluten exposure.

However, the study had limitations. It was conducted at a single center and focused only on stable adults. It did not deeply explore patient satisfaction beyond stated preferences. It also did not compare outcomes directly with traditional in-person annual reviews.

Future research could validate the questionnaire more formally, explore barriers among those who did not engage, and evaluate whether similar results occur in other regions or healthcare systems.

Why This Study Matters for People With Celiac Disease

For people living with celiac disease, access to regular specialist follow-up can make a meaningful difference in long-term health. Yet many patients report not receiving annual reviews at all.

This study demonstrates that a thoughtfully designed digital review system can safely and efficiently monitor stable patients while preserving specialist resources for those with active concerns. It shows that digital healthcare does not necessarily reduce quality; in some cases, it may enhance convenience, honesty in reporting, and system sustainability.

For patients, this model offers greater flexibility and potentially faster access to care when problems arise. For health systems, it provides a scalable solution to growing demand.

Ultimately, this research supports a blended approach to celiac care—one that combines digital monitoring for stable individuals with timely, personalized follow-up when needed. As the population of adults living with celiac disease continues to grow, innovative models like this may help ensure that no patient goes without the ongoing support required to maintain lifelong gluten-free health.

Read more at: pmc.ncbi.nlm.nih.gov

Celiac.com 03/09/2026 - Celiac disease is a lifelong autoimmune condition in which eating gluten causes the immune system to attack the lining of the small intestine. Gluten is a group of proteins found in wheat, barley, and rye. For people who are genetically susceptible, gluten exposure leads to inflammation, intestinal damage, and a wide range of symptoms that can affect nearly every system in the body. Although a strict gluten-free diet remains the foundation of treatment, many people with celiac disease continue to experience symptoms or incomplete healing even when they carefully avoid gluten. This narrative review explores emerging strategies that may help support people with celiac disease beyond dietary avoidance alone.

Why Gluten Is So Problematic in Celiac Disease

Gluten proteins are unusually difficult for the human digestive system to break down. They contain specific amino acids that resist normal digestion, leaving behind fragments that remain intact as they pass through the gut. In people with celiac disease, these fragments can cross the intestinal lining and trigger an immune response. Once this process begins, immune cells attack the lining of the small intestine, leading to villous damage, impaired nutrient absorption, and chronic inflammation.

This immune reaction does not require large amounts of gluten. Even trace exposure from cross-contact can keep the immune system activated. Over time, ongoing inflammation can lead to complications such as anemia, bone loss, neurological symptoms, infertility, and in severe cases, intestinal cancers. These risks explain why strict gluten avoidance is necessary, but they also highlight why accidental exposure remains such a serious concern.

Limitations of the Gluten-Free Diet

While the gluten-free diet is effective for many people, it is not a perfect solution. Gluten is widespread in processed foods, restaurants, and shared kitchens, making accidental exposure common. Many people with celiac disease report ongoing digestive symptoms, fatigue, or brain fog despite careful adherence. Studies have shown that a significant number of adults do not achieve full intestinal healing even after years on a gluten-free diet.

The diet itself can also be socially and financially burdensome. Gluten-free foods often cost significantly more than their gluten-containing counterparts, and safe options may be limited in certain regions. The constant need to read labels, question food preparation, and avoid social situations can lead to stress, anxiety, and reduced quality of life. These challenges have driven researchers to explore additional ways to reduce gluten-related harm.

Using Enzymes to Break Down Gluten

One promising area of research involves enzymes that can break down gluten proteins before they trigger the immune system. Certain bacteria and fungi naturally produce enzymes capable of cutting gluten into smaller fragments that are less likely to cause harm. These enzymes target specific parts of gluten that human digestive enzymes cannot handle.

Some of these enzymes work best in the small intestine, while others are active in the stomach. Their ability to function in different digestive environments is important, since early breakdown of gluten may reduce the amount that reaches sensitive areas of the gut. Research has shown that these enzymes can reduce the immune-stimulating potential of gluten in laboratory and animal studies, and some human trials suggest they may lessen intestinal injury during controlled gluten exposure.

However, these enzyme therapies are not intended to replace a gluten-free diet. Instead, they are being studied as tools to reduce the impact of accidental or unavoidable gluten exposure. Results from clinical trials have been mixed, indicating that while enzymes may help some individuals, they are not a complete solution and require further research.

Protecting the Intestinal Barrier

Another important target in celiac disease is the intestinal barrier itself. In healthy individuals, the cells lining the intestine form tight connections that prevent large food particles from crossing into the immune system. In celiac disease, these connections become loosened, allowing gluten fragments to pass through more easily.

Researchers have investigated compounds designed to strengthen these cellular connections and reduce intestinal permeability. By limiting how much gluten crosses the intestinal barrier, these approaches aim to reduce immune activation even when small amounts of gluten are present. Clinical studies have shown that certain compounds may reduce symptoms and immune responses during gluten exposure, although they do not appear to completely restore normal barrier function.

Despite promising early results, development of these treatments has faced challenges, and large-scale studies are still needed to determine their long-term role in managing celiac disease.

The Role of Gut Bacteria

The community of bacteria living in the digestive tract plays a critical role in digestion, immune regulation, and intestinal health. People with celiac disease often show an imbalance in these bacterial populations, with fewer beneficial species and more inflammatory ones. This imbalance can persist even after long-term adherence to a gluten-free diet.

Some beneficial bacteria are capable of breaking down gluten fragments or reducing inflammation in the gut. Research suggests that certain bacterial strains may help counteract the harmful effects of gluten by modifying immune responses or supporting the integrity of the intestinal lining. Animal studies and early human research indicate that restoring a healthier bacterial balance may reduce inflammation and improve symptoms.

While probiotics are widely available, not all strains are helpful for celiac disease, and benefits may vary from person to person. Ongoing research aims to identify specific bacteria that could be used more effectively as supportive therapy.

Plant-Derived Enzymes and Gluten Detoxification

Plants also offer intriguing possibilities for gluten management. During the germination process, certain grains produce enzymes that naturally break down storage proteins, including gluten. These plant-derived enzymes have been shown to reduce the size and immune-stimulating potential of gluten fragments in laboratory studies.

Some of these enzymes can break gluten into very small pieces that are less likely to activate the immune system. This raises the possibility of using plant enzymes during food processing to create products with lower gluten activity. Such approaches could improve the safety of gluten-free foods and reduce the risk associated with trace contamination.

Although these methods are still under investigation, they represent an innovative way to address gluten exposure before food is even consumed.

Improving Gluten-Free Food Safety

Beyond individual treatments, enzymatic approaches may also be applied during food production. By using enzymes to break down gluten during processing, manufacturers may be able to create foods that are safer and more affordable for people with celiac disease. This could help address some of the financial and accessibility challenges associated with the gluten-free diet.

Such applications must be carefully regulated and thoroughly tested to ensure safety, but they offer a promising avenue for improving everyday life for those who rely on gluten-free foods.

Why This Research Matters for People With Celiac Disease

This review highlights the growing recognition that celiac disease management may benefit from a multi-layered approach. While strict gluten avoidance remains essential, additional strategies could help reduce the impact of accidental exposure, support intestinal healing, and improve quality of life. Enzymes from bacteria, fungi, and plants, along with methods to strengthen the intestinal barrier and support gut bacteria, all offer potential benefits.

For people with celiac disease, these developments represent hope for better symptom control and fewer disruptions from unavoidable gluten exposure. Although none of these approaches replace the gluten-free diet, they may eventually serve as valuable tools alongside it. Continued research is essential, but this work underscores an important message: managing celiac disease may one day involve more than avoidance alone, offering greater resilience and confidence in daily life.

Read more at: cureus.com

Celiac.com 01/07/2026 - This study explores an entirely new way to diagnose celiac disease and its earliest form, potential celiac disease, using only a small blood sample. By combining infrared spectroscopy with advanced deep learning, the researchers created a method that may be faster, less invasive, and more accurate than traditional diagnostic approaches.

Background: Why Diagnosing Celiac Disease Is Difficult

Celiac disease is an autoimmune condition in which eating gluten triggers the immune system to attack the lining of the small intestine. This damage can lead to digestive problems, nutrient deficiencies, fatigue, bone loss, and many other symptoms. Traditionally, diagnosis requires a combination of blood tests and an intestinal biopsy taken by endoscopy. Biopsies are considered the gold standard, but they are invasive, expensive, and not always available in all parts of the world.

There is another category called potential celiac disease. These individuals show immune signs of celiac disease and have the same genetic risk, but their intestinal tissue may appear normal or only slightly inflamed. These early changes are difficult to identify, and many people with potential celiac disease eventually progress to the full form of the condition. Because their symptoms can be mild or unpredictable, diagnosing potential celiac disease accurately and early is especially challenging.

This study set out to address these challenges by exploring whether the unique chemical “fingerprints” found in a person’s blood could reveal whether they have celiac disease, potential celiac disease, or no disease at all.

Using Infrared Light to Detect Disease Signals in Blood

The researchers used a technique called Fourier-transform infrared spectroscopy. In simple terms, this method shines infrared light through a drop of serum taken from the blood. Different molecules—such as fats, proteins, and nucleic acids—absorb the light in different ways. This pattern of absorption creates a detailed “spectral fingerprint” that reflects the molecular composition of the sample.

Because celiac disease disrupts immune activity, nutrient absorption, fat processing, and inflammation, the composition of the blood changes. These changes may be too subtle for a human to detect by reading a spectrum, but advanced computer algorithms can recognize patterns hidden within the data.

Why Deep Learning Was Essential

Infrared spectral data is extremely detailed and contains both useful information and background noise. Traditional statistical tools can analyze some parts of the spectrum, but they often miss faint signals or cannot combine many layers of information at once.

To solve this, the researchers built a deep learning system with two specialized branches. One branch focuses on global patterns across the entire spectrum, capturing long-range relationships between different wavelengths. The other branch highlights smaller, more focused features that appear in specific parts of the spectrum. By combining both types of information, the model can pay attention to subtle changes that separate the three groups—celiac disease, potential celiac disease, and healthy individuals.

This design helps the model recognize even faint disease signals that would normally be hidden by noise or too complex for older techniques.

What the Spectral Data Revealed

When comparing spectra from individuals with celiac disease, potential celiac disease, and healthy individuals, the research team found clear differences in several regions. These variations appear to reflect shifts in important biological processes:

• Changes in lipid-related signals, likely linked to impaired fat absorption caused by damaged intestinal villi.
• Increases in markers connected to inflammation and oxidative stress, which are common in immune-driven intestinal injury.
• Alterations in protein and nucleic acid signatures, possibly reflecting immune activation and tissue repair processes.

People with potential celiac disease showed some of the most distinct spectral patterns, suggesting that their blood chemistry contains early warning signs of disease activity even before structural damage becomes visible in the intestine.

How the New Model Compared to Existing Methods

The research team compared their hybrid dual-path deep learning model to eleven other machine learning and deep learning systems. These included commonly used methods such as support vector machines, random forests, logistic regression, and several well-known neural network structures.

The new model outperformed all of them across every major measurement. It achieved the highest accuracy, the best ability to correctly identify true cases, and the strongest discrimination between the three groups. Its accuracy rate was more than ninety-four percent, and its ability to identify potential celiac disease—typically the hardest category to classify—was significantly better than all baseline models.

Because the model can detect early-stage patterns with such sensitivity, it may help identify disease long before major tissue damage occurs.

Why This Matters for Real-World Diagnosis

Current diagnostic pathways involve multiple steps, including antibody tests, genetic testing, and intestinal biopsies. These procedures can be costly, require specialized equipment, and may not be available in all healthcare settings. In addition, biopsies require time, skilled specialists, and patient cooperation, which can be difficult in children and individuals with limited access to medical care.

The approach developed in this study uses only a blood sample, relies on equipment that is more affordable and widely available than endoscopic tools or mass spectrometry systems, and produces results in less than an hour. It does not require a pathologist to interpret tissue samples, nor does it depend on the quality of biopsy material.

This makes it especially valuable for early screening, follow-up evaluations, and diagnosis in regions with limited medical resources.

What the Study Means for People With Celiac Disease

This research opens the door to a future where diagnosing celiac disease could be faster, easier, and less invasive. For people living with the condition, or those who may be at risk, the findings have several important implications:

• Earlier detection: The method may identify potential celiac disease before significant intestinal injury occurs, allowing individuals to begin treatment sooner.
• Fewer invasive procedures: Many patients may not need repeat biopsies during follow-up, reducing discomfort and cost.
• Better monitoring: A simple blood-based tool could allow doctors to track disease activity more frequently, helping ensure that a gluten-free diet is effective.
• Greater global accessibility: Healthcare systems with limited resources may be able to perform rapid screening at a much lower cost.

Overall, this study demonstrates that infrared spectroscopy combined with deep learning has the potential to transform how celiac disease is detected and managed. By capturing hidden molecular signals in the blood, this technique may provide a powerful new way to support diagnosis, guide treatment, and improve long-term outcomes for people with celiac disease and those who are beginning to show early signs of it.

Read more at: nature.com

Celiac.com 01/05/2026 - Celiac disease is an immune-driven condition in which the body responds aggressively to gluten, a protein found in wheat, barley, and rye. This reaction damages the small intestine, leads to painful symptoms, and causes long-term health complications if untreated. At present, the only effective therapy is a lifelong gluten-free diet. For many people, this diet is expensive, restrictive, and difficult to follow perfectly. Even tiny amounts of gluten can trigger symptoms and intestinal injury.

A new study offers a glimpse into what future treatments might look like. Instead of avoiding gluten entirely, scientists explored whether it might be possible to retrain the immune system so it does not attack the body when gluten appears. Their approach involves modifying a special group of immune cells called regulatory T cells—cells whose natural role is to calm down excessive immune responses. The researchers found that carefully engineered versions of these cells were able to reduce gluten-driven immune reactions in animal models. While early, the findings suggest a new path toward treatments that address the root cause of celiac disease.

Understanding the Immune Players in Celiac Disease

The immune system contains many different kinds of cells. In celiac disease, a type of cell known as an effector T cell drives the harmful reaction. These cells recognize gluten as if it were dangerous and launch an attack that damages the lining of the small intestine.

Another type of cell, called a regulatory T cell, normally helps prevent the immune system from overreacting. In healthy individuals, regulatory T cells help maintain balance by slowing or stopping immune responses when they are no longer needed. In celiac disease, however, the natural regulatory T cell response is not strong enough to counteract the aggressive behavior of effector T cells.

The study explored whether increasing or improving regulatory T cells could calm the immune system when gluten is present.

Precision Editing of Regulatory T Cells

Researchers used an advanced gene-editing technique to modify regulatory T cells and effector T cells so that each responded to very specific gluten fragments. They selected two gluten fragments that trigger strong immune reactions in most people with celiac disease. These fragments bind to a genetic marker called HLA-DQ2.5, a marker carried by the majority of celiac patients.

The scientists replaced the natural T cell receptors on the engineered cells with new receptors designed to recognize these gluten fragments precisely. This process allowed the modified regulatory T cells to become highly targeted: they could sense when gluten-reactive effector T cells were activated and then suppress their activity.

Testing the Therapy in a Mouse Model

To understand how these engineered cells behave inside a living system, the research team used mice bred to express the same human genetic marker associated with celiac disease. The team created two groups of engineered cells:

• Effector T cells that reacted strongly to gluten
• Regulatory T cells designed to suppress these reactions

Both types of engineered cells were introduced into the mice. When the mice were later given gluten, the effector T cells quickly moved toward the intestines and began to multiply—exactly as they do in human celiac disease.

However, when mice received the engineered regulatory T cells, the reaction changed dramatically. The dangerous effector T cells did not expand or travel to the gut. The regulatory T cells were able to shut down the response before it caused harm. This calming effect did not require the regulatory T cells to match the exact gluten fragment the effector cells were reacting to. Instead, the regulatory cells suppressed a broad range of gluten-related immune responses, a phenomenon known as bystander suppression.

Why Bystander Suppression Matters

Celiac disease is complicated because people do not react to just one gluten fragment—they respond to many. A major challenge in designing therapies is the wide variety of gluten proteins that can activate disease-causing immune cells.

The engineered regulatory T cells showed the ability to suppress effector cells targeting not only the same gluten fragment but also different, related fragments. This suggests that a therapy based on these engineered cells could calm the entire network of gluten-reactive immune responses, not just one narrow pathway.

Limitations and Questions for Future Research

While the study is encouraging, experts note several limitations that must be addressed before human trials become possible. The work was performed in mice, which do not naturally develop intestinal damage from gluten the way humans with celiac disease do. The experiment also tested gluten only once instead of repeatedly, so long-term effects remain unknown.

Additionally, people with celiac disease sometimes have fewer regulatory T cells, and in some cases those cells are less functional. It is not yet clear whether engineered regulatory T cells would behave the same way in a person whose immune system is already dysregulated.

More research is needed to understand when such a therapy would be most effective—for example, whether it should be used before symptoms develop or after the disease is already established.

What This Study Suggests for the Future

Despite the challenges, this research lays important groundwork. The approach adapts principles from cell therapies already being used in cancer treatment, raising the possibility that similar techniques could eventually help people with autoimmune diseases. The idea of restoring immune balance—rather than merely avoiding triggers—is an appealing shift.

If future studies support these findings, engineered regulatory T cells could one day help people with celiac disease tolerate accidental gluten exposure, reduce intestinal inflammation, or perhaps even allow a more flexible diet. For many patients, this could dramatically improve quality of life.

Why It Matters for People with Celiac Disease

The results of this study are particularly hopeful for those living with celiac disease. Current treatment relies entirely on dietary restriction, which is difficult to maintain and does not fully prevent complications for everyone. A therapy that calms the immune system’s reaction at its source could offer a deeper level of control over the disease.

While this research represents only an early step, it points toward a future in which celiac disease might be managed not by avoiding gluten completely, but by restoring harmony within the immune system itself. For patients and families affected by celiac disease, this possibility represents an exciting and meaningful shift in how the condition might one day be treated.

Read more at: science.org

Watch the video version of this article:

Watch the super short video version of this article:

Celiac.com 12/05/2025 - Many people are tested for celiac disease using blood tests that look for antibodies against tissue transglutaminase 2. High values are well known to match up with damage in the small intestine and often allow doctors to diagnose without a biopsy in select settings. Far less clear is what to do when results are just above the test cutoff (“low positive”) or sit just below it (“borderline negative”). This study followed a carefully defined group of adults to learn how often those softer results still signal true celiac disease or an early stage that deserves close follow-up.

Who Was Studied and How

Researchers examined 311 adults who either had symptoms that raised concern for celiac disease or had a family history of the condition. Everyone had blood tests and small-bowel biopsies. Blood testing included:

• Antibodies against tissue transglutaminase 2 (with the manufacturer’s cutoff for positivity at 7.0 units per milliliter).
• Endomysial antibodies, a highly specific companion test.
• Genetic testing for human leukocyte antigen types linked to celiac disease (human leukocyte antigen DQ2 or DQ8).

The team defined “low positive” as 7.0–14.0 units per milliliter and “borderline negative” as 3.0–6.9 units per milliliter. Beyond routine biopsy reading, they also looked for two tissue signs that mark celiac disease activity even at early stages: tissue transglutaminase 2-targeted antibody deposits in the intestinal lining and an increased number of a specific type of intraepithelial lymphocyte (called gamma delta cells).

Key Results at a Glance

• Low positive results were often real celiac disease. Among people with low positive transglutaminase 2 antibodies, almost nine in ten received a celiac disease diagnosis after combining biopsy, special tissue markers, and clinical response.
• Borderline negative did not rule out disease. In the borderline negative group, more than one in three were ultimately diagnosed with celiac disease. Among those who were also positive for endomysial antibodies, nearly four in five had celiac disease.
• Early activity was common even without a firm diagnosis. In people with borderline negative results who were not diagnosed, almost one in three still showed celiac-specific tissue changes or genetic risk that suggested an early or developing stage.
• Very high values were decisive. Every participant whose transglutaminase 2 antibody level reached at least 3.2 times the upper limit of normal received a diagnosis of celiac disease.

What “Low Positive” Really Means

A number just above the test cutoff can feel uncertain. This study shows that, in a specialist setting, low positive values often reflect genuine disease rather than test noise. Some people with low positive results did not yet have the classic level of intestinal damage, but they did have celiac-specific tissue deposits or increased gamma delta lymphocytes, and they improved or showed clear changes when gluten was removed or reintroduced under supervision. In other words, a low positive result can catch celiac disease early, before the intestinal lining is more severely injured.

What “Borderline Negative” Can Hide

Borderline negative numbers are below the standard cutoff, yet this study found that they can still be meaningful, especially when paired with endomysial antibody positivity or celiac-linked genes. A substantial portion of these individuals either already met criteria for celiac disease or showed early markers that warranted close follow-up. For families with a history of celiac disease, a borderline negative result should not be brushed off, particularly if symptoms are present.

The Special Role of Endomysial Antibodies

Endomysial antibodies were the tie-breaker in many ambiguous cases. When endomysial antibodies were positive alongside a low positive transglutaminase 2 result, every single person in that group had celiac disease. Even within the borderline negative range, a positive endomysial antibody result greatly raised the chance of a true diagnosis. While endomysial testing is more specialized and operator-dependent, this study supports using it as a second step whenever first-line results are borderline or only slightly positive.

How Doctors Might Use These Findings

• Treat results as a continuum, not a switch. Numbers near the cutoff should be interpreted with clinical judgment, genetics, and—when available—special tissue markers, not dismissed as “negative.”
• Repeat testing on a gluten-containing diet. For borderline or low results, retesting after several months can show whether antibodies are trending upward and can avoid missed or delayed diagnoses.
• Use endomysial antibodies to clarify. When available, endomysial testing can convert uncertainty into clarity, especially in the borderline zone.
• Do not forget the biopsy and tissue markers. Multiple biopsy samples, careful orientation, and, where possible, testing for transglutaminase 2-targeted deposits and gamma delta lymphocyte counts can reveal early disease.

Strengths and Limits

This study’s strengths include a clearly described adult cohort, comprehensive blood testing, and careful small-bowel evaluation with both standard pathology and celiac-specific tissue markers. It also included people tested because of symptoms and people screened due to family history. Limitations include the lack of data on medicines that might blunt antibody production, no measurement of deamidated gliadin peptide antibodies, and the fact that all participants already had a higher chance of disease than the general population. The results therefore guide specialist practice but should be applied thoughtfully in broader settings.

What This Means for People with Celiac Disease or at Risk

If your transglutaminase 2 antibody result is only slightly above the cutoff or just below it, do not assume it “does not count.” In this study, many people in those gray zones either had celiac disease already or showed early immune activity that called for close follow-up. If you also test positive for endomysial antibodies, the likelihood that this reflects true celiac disease is high. If you have symptoms or a family history, ask about repeat testing while still eating gluten, consider endomysial antibody testing, and discuss whether a biopsy and, if available, celiac-specific tissue markers are appropriate. Early identification matters: catching celiac disease before advanced intestinal damage develops can speed healing, reduce complications, and improve day-to-day wellbeing.

Bottom Line

Celiac blood tests live on a spectrum. “Low positive” often means real disease, and even “borderline negative” can signal celiac disease—especially when endomysial antibodies are present or when early tissue markers are detected. For patients and families, this supports a proactive approach: pair antibody results with symptoms, genetics, endomysial testing, and thoughtful biopsy strategies. For people living with celiac disease or at high risk, that approach can shorten the road to answers and help you start healing sooner.

Read more at:  onlinelibrary.wiley.com

Celiac.com 11/12/2025 - This summary explains a prospective study that followed children who were more likely than average to develop celiac disease because a parent or a sibling already had the condition. The researchers focused on a common blood marker used to detect celiac disease: tissue transglutaminase immunoglobulin A. The central question was simple but important: does this marker climb gradually in the months before it turns positive, or does it switch from normal to positive in a short window of time? The answer has direct consequences for how often families and clinicians should test children who are at higher risk.

Why This Question Matters

Celiac disease is an immune condition in which eating gluten damages the small intestine. Blood tests that look for antibodies against tissue transglutaminase are widely used to screen for the condition and to decide when an intestinal biopsy may be needed. For families with one child or parent already diagnosed, another child may be watched closely over the years. If the antibody level usually rose slowly, parents and doctors could look for a creeping trend as a warning sign. If the change tended to be sudden, trend-watching would be less helpful, and the strategy would shift toward testing at regular time points.

Who Was Studied and How

The study drew from a large, ongoing, prospective cohort of more than five hundred children who had a first-degree relative with celiac disease. Being “prospective” means the researchers planned the measurements in advance and followed the children forward in time, a design that helps reduce some forms of bias. From this group, the team identified thirty-four children who eventually developed a positive blood test for tissue transglutaminase immunoglobulin A during the study period.

For those thirty-four children, the investigators looked at two time points: the visit when the blood test first turned positive, and the visit roughly six months earlier. They then asked a focused question: were any of those earlier blood tests already drifting upward, or were they still firmly in the normal range?

What the Researchers Measured

The main measurement was the level of tissue transglutaminase immunoglobulin A in blood, a marker that usually becomes elevated when the immune system has begun to react to gluten in a way that harms the intestine. The team compared each child’s level at the time of first positivity with the level from about half a year before that moment. Because the children were enrolled prospectively and tested on a schedule, the study could capture the transition from negative to positive more cleanly than a one-time snapshot study.

Core Finding: Normal, Then Positive

All thirty-four children who later became positive had normal tissue transglutaminase immunoglobulin A levels six months earlier. There were no early warning drifts within that time window. In practical terms, this pattern suggests that, at least for many children in this risk group, the shift from a negative test to a positive test happens quickly rather than gradually.

What This Does and Does Not Mean

This study does not say that antibody levels can never rise slowly in any child. Biology is varied, and longer gaps between blood draws could miss a subtle ramp-up that begins more than six months before a positive test. The study also does not claim that a positive test always means intestinal damage has already occurred; the blood test is a strong screening tool, but diagnosis still relies on the full clinical picture and, in many cases, intestinal biopsy and follow-up.

What the study does show is that, within a six-month window before the first positive test, the children in this cohort did not display a gradual upward trend that could have been used to predict the change. In other words, watching for a slow climb in tissue transglutaminase immunoglobulin A was not useful for forecasting who would turn positive within half a year.

Strengths and Limitations

Strengths include the prospective design, which reduces recall problems and allows the timing of the change to be observed more accurately. The children were at clear, documented risk because of an affected parent or sibling, making the results relevant to families who live in that reality.

Limitations include the modest number of children who actually converted during the observation period, which was thirty-four out of more than five hundred enrolled. The time spacing between tests matters: if visits were roughly six months apart, the study could miss patterns that happen and resolve within shorter time frames, or much earlier than six months before positivity. The study also did not attempt to tie every blood test result to symptoms, diet changes, or infections that might influence the immune system.

Practical Takeaways for Families and Clinicians

• Do not rely on a gradual rise as an early warning sign. In this cohort, tests were normal six months before the first positive result. Expect a relatively abrupt shift rather than a slow climb.
• Use a scheduled testing plan for children at higher risk. Because a slow trend is not a reliable signal, the safer approach is to test at regular intervals recommended by your clinical team, and to test sooner if symptoms appear.
• Interpret a single negative test with care. A normal tissue transglutaminase immunoglobulin A level today does not guarantee that the test will remain negative in the near future. This is especially important for children with a parent or sibling who has celiac disease.
• Combine blood tests with the full clinical picture. Diagnosis and follow-up should consider symptoms, growth, nutritional status, genetics, and, when appropriate, intestinal biopsy findings.

Why This Matters for People with Celiac Disease and Gluten Sensitivity

For families already affected by celiac disease, this study offers a clear message: the blood marker most commonly used to screen for the condition can move from normal to positive between routine visits without giving an early hint. That means waiting to see a “creeping upward” trend is not a safe strategy. Instead, a plan built around regular screening is more protective, especially in childhood when early detection helps avoid nutritional problems and supports healthy growth.

For adults who are supporting children at risk, this information can reduce uncertainty and anxiety about tiny fluctuations. If the test is normal, it is reasonable to feel reassured for now, but it is also wise to keep the next scheduled test on the calendar. If the test turns positive, it is not a sign that something was “missed” for months; rather, it reflects how the immune response often changes over a short period.

For people who experience symptoms after eating gluten but do not have celiac disease, the takeaway is different: this study focused specifically on celiac disease antibody testing in children with a family history. It does not address non-celiac gluten sensitivity. However, it does reinforce a broader point: self-directed diet changes without appropriate testing can make diagnosis harder. If celiac disease is a concern, speak with a clinician about a proper testing plan before removing gluten from the diet.

Bottom Line

In children with a first-degree relative who has celiac disease, tissue transglutaminase immunoglobulin A usually stays normal until close to the time it turns positive. The change tends to be sudden rather than gradual over the prior six months. The most practical response is simple and family-friendly: follow a regular testing schedule, stay alert to new symptoms, and pair blood tests with clinical guidance. This approach improves the chances of catching celiac disease early, preventing complications, and supporting healthy growth and well-being.

Read more at: journals.lww.com

Celiac.com 09/22/2025 - Celiac disease is a condition in which the body reacts negatively to gluten, a protein found in wheat, barley, and rye. People with this disorder experience inflammation and damage in the small intestine when gluten is consumed. The standard treatment today is to follow a strict gluten-free diet, but this can be difficult to maintain and does not always fully relieve symptoms. Because of these challenges, researchers are searching for alternative or additional therapies that can make living with this condition easier.

One potential option is to use probiotics, which are helpful bacteria that naturally live in the human gut or are taken as supplements. This study explored whether a particular probiotic species, Lactobacillus rhamnosus, has the ability to help break down gluten and possibly reduce its harmful effects.

Purpose of the Study

The researchers aimed to evaluate whether Lactobacillus rhamnosus could serve as a gluten-digesting bacterium. By studying its genetic makeup, they hoped to identify whether this probiotic carries enzymes capable of degrading toxic gluten fragments. If successful, this discovery could open the door to new therapies that support people with celiac disease in addition to a gluten-free diet.

How the Study Was Conducted

Instead of testing the bacteria directly in the laboratory or in humans, the team used a computer-based, or bioinformatic, approach. They analyzed the complete genetic information of forty-nine different strains of Lactobacillus rhamnosus. This allowed them to search for specific genes that might produce enzymes capable of breaking down gluten proteins.

To carry out this analysis, the researchers used several tools that can identify and classify genes. They looked particularly for enzymes known as peptidases, which are proteins that cut other proteins into smaller fragments. Because gluten is a protein, the right types of peptidases could help reduce its harmful effects.

Main Findings

The study revealed that Lactobacillus rhamnosus carries sixty-one different peptidases in its genetic code. Among these, nine stood out because they shared important similarities with enzymes already known to break down gluten. These included:

• Aminopeptidase N
• Neutral endopeptidase
• Oligoendopeptidase F
• Dipeptidyl-peptidase 5
• Proline iminopeptidase
• Xaa-Pro dipeptidyl-peptidase
• Aminopeptidase C
• Aminopeptidase E
• PII-type proteinase

Each of these enzymes has features that suggest they could help cut apart gluten fragments, particularly gliadin peptides, which are the most damaging components of gluten for people with celiac disease. This means that Lactobacillus rhamnosus could have the ability to reduce gluten toxicity before it causes harm in the gut.

Why This Matters

These findings are important because they suggest that a widely used probiotic species may provide more benefits than previously recognized. Lactobacillus rhamnosus is already known to support digestive health and strengthen the immune system. If future research confirms that it can also break down gluten, it could become a valuable part of celiac disease management.

For people living with celiac disease, strict avoidance of gluten is the only proven way to stay healthy. However, accidental exposure is common and can lead to painful and damaging flare-ups. A probiotic that helps digest gluten could provide an added layer of protection and improve quality of life.

Conclusion

This study highlights the potential of Lactobacillus rhamnosus as a gluten-digesting bacterium. By analyzing its genetic structure, researchers identified several enzymes that may be able to break down harmful gluten fragments. Although more research is needed, especially in laboratory and human studies, this discovery is promising. For individuals with celiac disease, such a therapy could one day mean fewer accidental reactions, less worry, and a healthier, more flexible lifestyle.

Read more at: springer.com